Trending: Merck, Daiichi Sankyo Sign Development, Commercialization Deal
14:07 ET -- Merck is one of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. After the bell Thursday, Merck and Daiichi Sankyo announced a global development and commercialization collaboration for three Daiichi Sankyo DXd ADCs. On Friday, Merck released data showing its Keytruda in combination with other treatments showed statistically significant improvement in pathological complete response rate for certain breast cancer patients, and that it improved progression-free survival in certain patients with cervical cancer. Dow Jones & Co. owns Factiva. (stephen.nakrosis@wsj.com)
(END) Dow Jones Newswires
October 20, 2023 14:22 ET (18:22 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing
-
Going Into Earnings, Is Nvidia Stock a Buy, a Sell, or Fairly Valued?